Inspections, Compliance, Enforcement, and Criminal Investigations
Bristol Myers-Squibb Company Close out Letter 6/7/11
|
Public Health Service Food and Drug Administration |
| San Juan District 466 Fernandez Juncos Avenue San Juan PR 00901-3223 Telephone: (787) 474-9500 FAX: (787) 729-6658 |
June 7, 2011
WARNING LETTER CLOSE OUT LETTER
CERTIFIED MAIL
RETURN RECEIPT REQUESTED
Mr. Lamberto Andreotti
President and CEO
Bristol Myers- Squibb Company
345 Park Avenue
New York, NY 10154
Dear Mr. Andreotti:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter SJN-2010-06 dated 08/30/2010. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
Kind regards,
/S/
Edwin Ramos
Director of Compliance
San Juan District Office





Department of Health and Human Services

